

## Drug Monograph

Drug/Drug **Afrezza<sup>®</sup> (insulin human) inhalation powder/ Rapid Acting**  
 Class: **Insulins**  
 Prepared for: MO HealthNet  
 Prepared by: Conduent-Heritage

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Afrezza<sup>®</sup> is now available in a titration pack that contains 60 – 4 unit cartridges, 60 – 8 unit cartridges, and 60 – 12 unit cartridges of insulin human.

**Manufacturer:** MannKind Corporation, Danbury, CT 06810

**Indications:** Afrezza<sup>®</sup> is rapid acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

**Costs:** \$592.20 per titration pack of Afrezza<sup>®</sup>. Wholesale Acquisition Cost

**Summary of Findings:** This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

**Status Recommendation:**  Prior Authorization (PA) Required  Open Access  
 Fiscal Edit  PDL

**Type of PA Criteria:**  Increased Risk of ADE  Under Solicitation  
 Appropriate Indications  Non Preferred

Prepared By: Luke Boehmer Pharm.D.  
 Date: May 10, 2017